Dexamethasone therapy for isosexual precocious pseudopuberty caused by generalized glucocorticoid resistance

Carl D. Malchoff, George Reardon, Emmanuel C. Javier, Alan D. Rogol, Patrick McDermott, D. Lynn Loriaux, Diana M. Malchoff

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Generalized glucocorticoid resistance presents with clinical features secondary to excess production of mineralocorticoids and adrenal androgens. It is our hypothesis that these clinical and biochemical features will respond to glucocorticoid therapy. We tested this hypothesis in a boy with generalized glucocorticoid resistance and increased adrenal androgens. Dexamethasone was administered from age 7 6/12 yr until the onset of true puberty at 11 0/12 yr. Serum concentrations of cortisol and adrenal androgens decreased to the normal or near normal range. The accelerated precocity improved. Secondary sex characteristics did not progress; the difference between bone age and chronological age decreased from 3 1/2 yr to 2 yr, and the difference between height age and bone age decreased from 2 yr to 1/2 yr. We conclude that dexamethasone is effective and safe therapy for the sexual precocity of generalized glucocorticoid resistance.

Original languageEnglish (US)
Pages (from-to)1632-1636
Number of pages5
JournalJournal of Clinical Endocrinology and Metabolism
Issue number6
StatePublished - Dec 1994

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical


Dive into the research topics of 'Dexamethasone therapy for isosexual precocious pseudopuberty caused by generalized glucocorticoid resistance'. Together they form a unique fingerprint.

Cite this